Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Related Citations for PubMed (Select 20925435)

1.

Progressive multifocal leukoencephalopathy and newer biological agents.

Berger JR.

Drug Saf. 2010 Nov 1;33(11):969-83. doi: 10.2165/11537510-000000000-00000. Review.

PMID:
20925435
2.

Monoclonal antibodies and progressive multifocal leukoencephalopathy.

Berger JR, Houff SA, Major EO.

MAbs. 2009 Nov-Dec;1(6):583-9.

3.

Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab.

Berger JR, Houff S.

Neurol Res. 2006 Apr;28(3):299-305. Review.

PMID:
16687057
4.

Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps.

Zaheer F, Berger JR.

Ther Adv Drug Saf. 2012 Oct;3(5):227-39. doi: 10.1177/2042098612453849. Review.

5.

PML and rheumatology: the contribution of disease and drugs.

Molloy ES.

Cleve Clin J Med. 2011 Nov;78 Suppl 2:S28-32. doi: 10.3949/ccjm.78.s2.07.

PMID:
22123931
6.

Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies.

Tavazzi E, Ferrante P, Khalili K.

Clin Microbiol Infect. 2011 Dec;17(12):1776-80. doi: 10.1111/j.1469-0691.2011.03653.x. Review.

7.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.

N Engl J Med. 2012 May 17;366(20):1870-80. doi: 10.1056/NEJMoa1107829.

8.

Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.

Bellizzi A, Nardis C, Anzivino E, Rodìo D, Fioriti D, Mischitelli M, Chiarini F, Pietropaolo V.

J Neurovirol. 2012 Feb;18(1):1-11. doi: 10.1007/s13365-012-0080-7. Review.

PMID:
22290500
9.

The pathogenesis of progressive multifocal leukoencephalopathy.

Berger JR, Khalili K.

Discov Med. 2011 Dec;12(67):495-503. Review.

10.

Progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab.

Gadzia J, Turner J.

J Drugs Dermatol. 2010 Aug;9(8):1005-9.

PMID:
20684152
11.

Review of progressive multifocal leukoencephalopathy and natalizumab.

Aksamit AJ.

Neurologist. 2006 Nov;12(6):293-8. Review.

PMID:
17122725
12.

Monoclonal antibodies and progressive multifocal leukoencephalopathy.

Keene DL, Legare C, Taylor E, Gallivan J, Cawthorn GM, Vu D.

Can J Neurol Sci. 2011 Jul;38(4):565-71. Review.

PMID:
21672696
13.

Progressive multifocal leukoencephalopathy in multiple sclerosis.

Chalkley JJ, Berger JR.

Curr Neurol Neurosci Rep. 2013 Dec;13(12):408. doi: 10.1007/s11910-013-0408-6. Review.

PMID:
24136456
14.
15.

Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients.

Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M, Dal Pan G.

J Am Acad Dermatol. 2011 Sep;65(3):546-51. doi: 10.1016/j.jaad.2010.05.033. Epub 2011 Apr 22.

PMID:
21514689
16.

Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.

Baldwin KJ, Hogg JP.

Curr Opin Neurol. 2013 Jun;26(3):318-23. doi: 10.1097/WCO.0b013e328360279f. Review.

PMID:
23493158
17.

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies.

Major EO.

Annu Rev Med. 2010;61:35-47. doi: 10.1146/annurev.med.080708.082655. Review.

PMID:
19719397
18.

The link between VLA-4 and JC virus reactivation.

Monaco MC, Major EO.

Expert Rev Clin Immunol. 2012 Jan;8(1):63-72. doi: 10.1586/eci.11.85. Review.

PMID:
22149341
19.

Progressive multifocal leukoencephalopathy.

Berger JR.

Curr Neurol Neurosci Rep. 2007 Nov;7(6):461-9. Review.

PMID:
17999891
20.

[[Natalizumab therapy, 2013].

Karácsony M, Bencsik K, Vécsei L.

Ideggyogy Sz. 2014 Jul 30;67(7-8):220-8. Review. Hungarian.

PMID:
25509362
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk